Treatment of HSV Epithelial Keratitis

Primary Treatment Approach

The American Academy of Ophthalmology recommends initiating combination therapy with both topical antiviral (ganciclovir 0.15% gel 3-5 times daily OR trifluridine 1% solution 5-8 times daily) AND oral antiviral (acyclovir 400 mg five times daily, valacyclovir 500 mg 2-3 times daily, OR famciclovir 250 mg twice daily) for patients with HSV epithelial keratitis, as oral therapy alone is insufficient to prevent progression of corneal disease 1, 2
Ganciclovir 0.15% ophthalmic gel 3-5 times daily is the preferred first-line topical agent due to superior tolerability and less ocular surface toxicity compared to alternatives, with a healing rate of dendritic ulcers within 7 days in the majority of patients 1, 2

Topical corticosteroids are absolutely contraindicated in HSV epithelial keratitis as they potentiate viral replication and worsen infection, according to the American Academy of Ophthalmology 1, 2
The American Academy of Ophthalmology recommends scheduling follow-up within 1 week, including visual acuity measurement and slit-lamp biomicroscopy, to monitor the treatment of HSV epithelial keratitis 1, 2

The American Academy of Ophthalmology advises against using oral antivirals as monotherapy for active epithelial keratitis, as topical therapy is essential for corneal disease control, and against prescribing corticosteroids for epithelial disease, even if inflammation appears significant 1, 2
Consider higher antiviral doses in cases demonstrating apparent resistance to standard therapy, as recommended by the American Academy of Ophthalmology 1, 2

Trifluridine 1 % ophthalmic solution administered 5–8 times daily is associated with epithelial toxicity when treatment exceeds two weeks, limiting its use as a long‑term option. 3

Topical corticosteroids are absolutely contraindicated in HSV epithelial keratitis because they enhance viral replication and can worsen the infection. This prohibition is supported by multiple ophthalmology guideline statements. [3][4]

Patients should be re‑evaluated within one week of initiating therapy, including measurement of visual acuity and slit‑lamp biomicroscopy, to assess treatment response and detect early complications. [3][4]

Lower‑dose oral antiviral agents are recommended for suppressive therapy to prevent recurrent HSV keratitis episodes. The dosing strategy is based on guideline recommendations for long‑term prophylaxis. [3][4]